Caveolin-1 promotes Ewing sarcoma metastasis regulating MMP-9 expression through MAPK/ERK pathway by Lagares-Tena, Laura et al.
Caveolin-1 promotes Ewing sarcoma
metastasis regulating MMP-9
expression through MAPK/ERK pathway
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Lagares-Tena, L., S. García-Monclús, R. López-Alemany, O.
Almacellas-Rabaiget, J. Huertas-Martínez, M. Sáinz-Jaspeado,
S. Mateo-Lozano, et al. 2016. “Caveolin-1 promotes Ewing
sarcoma metastasis regulating MMP-9 expression through MAPK/
ERK pathway.” Oncotarget 7 (35): 56889-56903. doi:10.18632/
oncotarget.10872. http://dx.doi.org/10.18632/oncotarget.10872.
Published Version doi:10.18632/oncotarget.10872
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:31731696
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Oncotarget56889www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 35
Caveolin-1 promotes Ewing sarcoma metastasis regulating 
MMP-9 expression through MAPK/ERK pathway
Laura Lagares-Tena1, Silvia García-Monclús1, Roser López-Alemany1, Olga 
Almacellas-Rabaiget1, Juan Huertas-Martínez1, Miguel Sáinz-Jaspeado1, Silvia 
Mateo-Lozano2, Carlos Rodríguez-Galindo3, Santiago Rello-Varona1, David 
Herrero-Martín1, Oscar M. Tirado1
1Sarcoma Research Group, Institut d’Investigació Biomèdica de Bellvitge-IDIBELL, L’Hospitalet de Llobregat, Barcelona, 
Spain
2Developmental Tumor Biology Laboratory, Hospital Sant Joan de Deu, Barcelona, Spain
3Pediatric Hematology/Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, 
Boston, Massachusetts, USA
Correspondence to: Oscar M. Tirado, email: omartinez@idibell.cat
Keywords: caveolin-1, Ewing sarcoma, metastasis, mmp9, mapk 
Received: December 22, 2015    Accepted: July 18, 2016    Published: July 28, 2016
ABSTRACT
Ewing sarcoma (ES) is a bone and soft tissue sarcoma affecting mostly children 
and young adults. Caveolin-1 (CAV1) is a well-known target of EWS/FLI1, the main 
driver of ES, with an oncogenic role in ES. We have previously described how CAV1 
is able to induce metastasis in ES via matrix metalloproteinase-9 (MMP-9). In the 
present study we showed how CAV1 silencing in ES reduced MEK1/2 and ERK1/2 
phosphorylation. Accordingly, chemical inhibition of MEK1/2 resulted in reduction in 
MMP-9 expression and activity that correlated with reduced migration and invasion. 
IQ Motif Containing GTPase Activating Protein 1 (IQGAP1) silencing reduced 
MEK1/2 and ERK1/2 phosphorylation and MMP-9 expression. Furthermore, IQGAP1 
silenced cells showed a marked decrease in their migratory and invasive capacity. 
We demonstrated that CAV1 and IQGAP1 localize in close proximity at the cellular 
edge, thus IQGAP1 could be the connecting node between CAV1 and MEK/ERK in ES 
metastatic phenotype. Analysis of the phosphorylation profile of CAV1-silenced cells 
showed a decrease of p-ribosomal protein S6 (RPS6). RPS6 can be phosphorylated 
by p90 ribosomal S6 kinases (RSK) proteins. CAV1-silenced cells showed reduced 
levels of p-RSK1 and treatment with U0126 provoked the same effect. Despite not 
affecting ERK1/2 and RPS6 phosphorylation status neither MMP-9 expression nor 
activity, RSK1 silencing resulted in a reduced migratory and invasive capacity in vitro 
and reduced incidence of metastases in vivo in a novel orthotopic model. The present 
work provides new insights into CAV1-driven metastatic process in ES unveiling 
novel key nodes.
INTRODUCTION
ES is the second most common bone tumor in 
children and adolescents. This tumor is very aggressive 
and highly metastatic. Approximately, one third of ES 
patients present metastasis at diagnosis, being lung and 
bone marrow the most common sites. The treatment 
and prognosis of ES patients are determined among 
other factors by the presence of metastases. The 5-year 
survival rate of metastatic patients ranges from 20 to 
45% depending on location (lung and bone/bone marrow 
respectively), compared to 60-70% of those with localized 
disease [1]. Therefore, in order to find new therapeutic 
targets, further advances in the knowledge of ES 
metastatic key regulators are mandatory.
ES tumors have a distinctive chromosomal 
translocation that gives rise to a fusion protein, most 
commonly EWS/FLI1 (85% of cases) [2, 3]. These fusion 
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proteins act as aberrant transcription factors, deregulating 
the expression of several target genes, therefore affecting 
different pathways involved in the initiation, maintenance 
and progression of the tumor [4-6]. Our group has 
previously described CAV1 as one of these target genes, 
demonstrating its role in the malignant phenotype of ES 
[7], promoting cell proliferation [8], angiogenesis [9], 
metastasis [10] and chemotherapy resistance [11].
Matrix metalloproteinases (MMPs) are implicated 
in extracellular matrix remodeling and have been related 
to metastasis progression [12-13]. Especially MMP-9 has 
been related to tumor aggressiveness in different tumor 
types, including sarcomas [14]. In ES CAV1 seems 
to regulate indirectly MMP-9 transcription [10], thus 
promoting tumor metastasis. MEK/ERK is a pathway 
constitutively activated in ES [15], thus ERK1/2 could be 
a putative mediator of CAV1 pro-invasive role. Hence, the 
goal of this study is to further understand the mechanism 
through which CAV1 exerts its role in ES metastatic 
behavior.
RESULTS
MEK1/2 and ERK1/2 phosphorylation is 
reduced in CAV1-knockdown cells
The MEK/ERK pathway has been previously 
related with MMP-9 expression and regulation of 
invasion [16]. As A673 ES cells bear an activating 
mutation (V599E) in B-Raf, ERK1/2 could be a good 
candidate for MMP-9 regulation [17]. As expected, we 
detected in A673 cells more phosphorylated ERK1/2 
than in other ES cell lines harbouring the same EWS/
FLI1 fusion type (TC71, TC252, RH1, EW7) (Figure 
1A). Moreover, we found a decrease in ERK1/2 
phosphorylation in our previously published CAV1-
knockdown models (Figure 1B). We also observed 
a reduction in the phosphorylated form of the direct 
activator of ERK1/2, MEK1/2 (Figure 1B). These 
results correlated with an inhibition of MMP-9 at the 
transcriptional level (Supplementary Figure S1) [10].
We further investigated the involvement of MEK/
ERK pathway in the reduced invasive phenotype 
described in CAV1-knockdown ES models [10]. We 
treated A673 and TC71 cells with a specific MEK1/2 
inhibitor, U0126. As expected, after 24 h we observed a 
decrease in MEK1/2 and ERK1/2 phosphorylation levels 
as shown in Figure 2A. The same inhibitory effect was 
confirmed in MMP-9 expression and proteolytic activity 
(Figure 2B and 2C). Additionally, U0126-treated cells 
migrated significantly less than the untreated ones 
(Figure 2D) and showed a lower invasive capacity 
(Figure 2E), thus partially reproducing the observed 
phenotype in CAV1-silenced cells. These observations 
strongly suggest that p-ERK1/2 could be implicated in 
the CAV1-dependent regulation of MMP-9 transcription 
in ES cells.
IQGAP1 links CAV1 and MEK/ERK in ES 
migration and invasion
IQGAP1 has been involved in invasion [18] and 
linked to ERK2 modulating its activity [19]. Thus, 
IQGAP1 could be playing a similar role in ES. First, 
we checked that all ES cell lines expressed IQGAP1 
(Figure 3A). Then, we obtained a stable silencing model 
of IQGAP1 in the ES cell line A673. IQGAP1-silenced 
cells showed a reduction in p-MEK1/2 and p-ERK1/2 
levels (Figure 3B). Likewise, knockdown of IQGAP1 
diminished MMP-9 expression and the migratory and 
invasive capacity of A673 cells (Figure 3C-3E). Finally, 
by sucrose gradient and co-immunofluorescence (IF) 
experiments in A673 and TC71 cells we were able to 
show a close pattern of distribution of IQGAP1 and 
CAV1 at the cellular edge, particularly in membrane 
protusions (Figure 3F and 3G). These results suggest 
that IQGAP1 could be acting as a scaffold between 
CAV1 and MEK/ERK pathway in the metastatic 
phenotype of ES cells.
RPS6 and RSK1 phosphorylation is decreased in 
CAV1-silenced cells
The activation of ERK1/2 pathway can be 
triggered by different membrane receptors [20]. We 
analyzed the phosphorylation profile of the A673 
CAV1-knockdown model focusing on several Tyr-
kinase receptors, as well as different intracellular 
signaling nodes. Surprisingly, the only significant 
change that we were able to detect was a reduction in 
RPS6 phosphorylation (Figure 4A) (Supplementary 
Table S1). The decrease in p-RPS6 was then confirmed 
in two CAV1-silenced models (Figure 4B). Both RPS6 
and p-RPS6 are well expressed in ES cell lines (Figure 
4C). We proceeded to check, by immunohistochemistry 
(IHC), the status of p-RPS6 in a tissue microarray 
(TMA) of 26 ES patients [21-22]. We found a significant 
correlation between high p-RPS6 levels and prolonged 
survival of ES patients (Supplementary Figure S2, 
Supplementary Table S2). Although RPS6 is described 
as a main target of the mTOR pathway it can also be 
phosphorylated on Ser235/236 by RSK proteins in an 
ERK1/2-dependent manner [23]. RSK family proteins 
are involved in several cellular functions such as cell 
cycle regulation, migration and survival [24-25]. 
RSK family comprises four members, RSK1-4, that 
can be phosphorylated by ERK1/2 [24]. ES cell lines 
express similar levels of RSK1 although there are 
higher variations regarding RSK2 (Figure 5A and 5B); 
however, neither RSK3 nor RSK4 were detected (data 
not shown). We could appreciate clear differences in the 
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Figure 1: MEK1/2 and ERK1/2 phosphorylation is reduced in CAV1-knockdown cells. A. Representative western blot 
showing the phosphorylation and expression levels of ERK1/2 in different ES cell lines. B. Representative blots of MEK1/2 and ERK1/2, 
either total or phosphorylated, in A673, TC71 and A4573 CAV1-silenced models. α-tubulin was used as loading control. Quantification of 
the phosphorylated vs. total ratios is shown below each set of blots. Statistical significance was achieved by the Student’s t test: *p≤0.05 
**p≤0.001 ***p≤0.0001.
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phosphorylation status of RSK1 and RSK2 among the 
ES cell lines tested (Figure 5A and 5B). We focused our 
attention in the expression and phosphorylation status of 
RSK1 in A673 and TC71 CAV1-silenced models. RSK1 
phosphorylation levels were reduced in shCAV1 cells 
(Figure 5C). Furthermore, when treated during 24 h with 
U0126, not only RSK1 but also RPS6 phosphorylation 
levels were reduced in both cell lines (Figure 5D).
RSK1 silencing did not affect RPS6 
phosphorylation nor MMP-9 expression and 
activity
As we observed lower RSK1 phosphorylation in 
CAV1-knockdown cells, we analyzed the specific role 
of this protein in the CAV1-depentent MMP-9 regulation 
in ES cells. With that purpose, we established a specific 
Figure 2: MEK1/2 inhibitor U0126 reduced MMP-9 expression and activity and diminished migration and invasion in 
ES cell lines. A. Representative blots of MEK1/2 and ERK1/2, either total or phosphorylated, in A673 and TC71 cell lines treated with 
vehicle (DMSO) or 20 μM U0126. Quantification of the phosphorylated vs. total ratios is shown below the blot. B. Semi-quantitative RT-
PCR and corresponding quantifications showing MMP-9/β-Actin ratio in A673 and TC71 cell lines treated with vehicle (DMSO) or 20 μM 
U0126. C. Zymogram and corresponding quantification of the MMP-9 gelatinase activity in A673 and TC71 cell lines treated with vehicle 
(DMSO) or 20 μM U0126. D. Quantification of the transwell migratory capacity of A673 and TC71 treated cells (U0126) regarding their 
controls (DMSO). E. Quantification of the matrigel-coated transwell invasive capacity of A673 and TC71 treated cells (U0126) regarding 
their controls (DMSO). Statistical significance was achieved by the Student’s t test: *p≤0.05 **p≤0.001 ***p≤0.0001.
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and stable RSK1-knockdown model in the A673 cell 
line. RSK1 silencing was effectively achieved without 
affecting RSK2 levels (Figure 6A). RSK1 interference 
did not cause any variation in the phosphorylation 
levels of ERK1/2 and RPS6 (Figure 6B) neither in 
MMP-9 expression and/or activity (Figure 6C and 6D). 
Nonetheless, RSK1-knockdown seemed to affect the 
migratory and the invasive capacity of shRSK1 A673 
Figure 3: IQGAP1 intermediates in CAV1-regulation of migratory and invasive capacity of ES cells. A. Representative 
western blot showing the expression levels of IQGAP1 in different ES cell lines. B. Representative blots of MEK1/2 and ERK1/2, either total 
or phosphorylated, in IQGAP1-interfered cells. α-tubulin was used as loading control in every panel. Quantification of the phosphorylated 
vs. total ratios is shown below each set of blots C. Quantitative real time RT-PCR showing MMP-9 levels (β-Actin as reference) in A673 
shIQGAP1 model. D. Quantification of the transwell migratory capacity in A673 IQGAP1-interfered cells. E. Quantification of the matrigel-
coated transwell invasive capacity in A673 IQGAP1-silenced model. F. Western blot of IQGAP1, ERK1/2 and CAV1 in sucrose gradient 
separation phases from A673 (left) and TC71 (right) cell lines. G. Confocal imaging showing IQGAP1 (green) and CAV1 (red) in A673 (left) 
and TC71 (right) cell lines. Scale bar 15 μm. Statistical significance was achieved by the Student’s t test: *p≤0.05 **p≤0.001 ***p≤0.0001.
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cells in vitro as both were drastically diminished (Figure 
6E and 6F). Although RPS6 phosphorylation and MMP-
9 regulation in ES seems to be independent of RSK1 
these results confirmed the important role of RSK1 in 
ES migration and invasion.
RSK1 silencing reduced the incidence of 
metastases in vivo
Our in vitro results suggest that RSK1 might have 
effects on migration and invasion of ES cells. Both steps 
are crucial for the occurrence of metastasis. Therefore, 
Figure 4: RPS6 phosphorylation is decreased in CAV1-silenced cells. A. RTK Signaling Antibody Array performed with A673 
CAV1-knockdown model. Quantification data of p-RPS6 expression corresponds to the circled spots. B. Representative blots of RPS6, either 
total or phosphorylated, in shCAV1 models. α-tubulin was used as loading control. C. Representative western blot showing the phosphorylation 
and expression levels of RPS6 in different ES cell lines. α-tubulin was used as loading control. Quantification of the phosphorylated vs. total 
ratios is shown below each set of blots. Statistical significance was achieved by the Student’s t test: *p≤0.05 **p≤0.001 ***p≤0.0001.
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we sought whether RSK1 silencing has any effect in 
vivo using an experimental metastatic assay. This first 
attempt based on i.v. injection of A673 RSK1-knockdown 
cells failed to show any difference on lung colonization 
(Supplementary Figure S3). Thus, we developed a 
modified version of a previously described orthotopic 
model [26], as we consider that this new methodological 
approach recapitulates more accurately the steps of 
metastasis in ES patients. Cells were injected into the 
gastrocnemius muscles of BALB/cnu/nu. Once primary 
tumor-bearing limbs reached a volume of 800 mm3, 
gastrocnemius muscles were surgically resected to reduce 
morbidity associated with excessive tumor growth and to 
allow metastases to form. A summary of the model and 
images of each step are depicted in Figure 7A and 7B. 
For all the different types of cells injected (shRSK1 vs. 
Figure 5: CAV1-knockdown and MEK1/2 inhibition reduced RSK1 phosphorylation levels. A. Representative western 
blot showing the phosphorylation and expression levels of RSK1 in different ES cell lines. B. Representative western blot showing the 
phosphorylation and expression levels of RSK2 in different ES cell lines. C. Representative blots of RSK1, either total or phosphorylated, 
in shCAV1 models. D. Representative blots of RSK1 and RPS6, either total or phosphorylated, in A673 and TC71 cell lines treated with 
vehicle (DMSO) or 20 μM U0126. α-tubulin was used as loading control in every panel. Quantification of the phosphorylated vs. total ratios 
is shown below each set of blots. Statistical significance was achieved by the Student’s t test: *p≤0.05 **p≤0.001 ***p≤0.0001.
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Figure 6: RSK1 silencing did not affect MMP-9 expression but abrogate both migration and invasion of ES cells. A. 
Immunoblot of RSK1 expression levels in A673 shRSK1. B. Representative blots of RSK1 and RPS6, either total or phosphorylated, 
in RSK1-silenced cells. α-tubulin was used as loading control. C. Semi-quantitative RT-PCR and corresponding quantification showing 
MMP-9/β-Actin ratio in A673 RSK1-knockdown model. D. Zymogram and corresponding quantification of the MMP-9 gelatinase activity 
in A673 shRSK1 cells. E. Quantification of the transwell migratory capacity of A673 RSK1-interfered cells. F. Quantification of the 
matrigel-coated transwell invasive capacity of A673 RSK1-knockdown low expression model. Statistical significance was achieved by the 
Student’s t test: *p≤0.05 **p≤0.001 ***p≤0.0001.
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control), the frequency of primary tumor occurrence was 
100%, thus showing no differences regarding growth rate 
or tumor size. Tumors were extracted between 18-20 days 
after inoculation and mice were sacrificed 60 days post-
injection, lungs extracted and the number of metastases 
counted. After histological examination of the lungs, 83% 
of mice injected with control cells showed presence of 
metastases, while in RSK1-silenced clones the metastases 
incidence was reduced to 33.33 % and 28.57% (Figure 
7C and 7D). These in vivo results are in concordance with 
those obtained in vitro, as RSK1 silencing has a drastic 
effect on migration and invasion and point to RSK1 as a 
key pro-metastatic agent in ES.
Figure 7: RSK1 silencing reduced the incidence of metastases in vivo in an ES orthotopical xenograft model. A and B. 
Scheme and pictures depicting A673 RSK1-knockdown model after orthotopical implantation inside gastrocnemius muscle and removal 
of muscle after primary tumor growth. C. Lung metastasis incidence in A673 RSK1-silenced cells after primary tumor removal. D. 
Representative images of lungs recovered from mice orthotopically injected with A673 shRSK1 cells (magnification, ×100). Drawings in 
Figure 7A are adapted from graphics deposited in Wikimedia Commons and Servier Medical Art under a Creative Commons Attribution 
3.0 Unported License.
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DISCUSSION
We have previously reported the oncogenic and pro-
invasive role of CAV1 in ES and how MMP-9 expression 
is reduced once CAV1 is silenced [7, 10]. MEK/ERK 
pathway is involved in several cellular processes as 
cell adhesion, cell cycle regulation, migration, survival, 
differentiation, proliferation, metabolism and/or protein 
expression [27]. MMP-9 regulation through ERK1/2 has 
been well characterized in a variety of cellular models 
[16, 28-29]. ERK1/2 is activated and has been related to 
metastasis in several cancers as hepatocellular carcinoma 
[30], lung cancer [31] or colorectal carcinoma [32]. 
Besides, constitutive activation of this pathway has been 
described in ES [15, 33]. ERK1/2 activity is regulated 
by CAV1 in different tumor types. For example CAV1 
silencing results in a decrease in ERK1/2 phosphorylation 
in colon cancer [34] and in metastatic lung cancer cells 
[35].
In the present work we have verified the 
activation of ERK1/2 in most of ES cell lines and how 
the phosphorylated forms of ERK1/2 and its precursor 
MEK1/2 were reduced in CAV1-silenced ES cells. 
Moreover, when treated with MEK1/2 inhibitor U0126, 
A673 and TC71 cells showed, besides p-MEK1/2 and 
p-ERK1/2 inhibition, lower MMP-9 expression, reduced 
proteolytic activity and cellular migration and invasion 
were impeded. These results are the same previously 
described in the CAV1-knockdown models [10]; thus 
we have found a correlation in ES between MEK1/2 
and ERK1/2 phosphorylation inhibition and a reduction 
in MMP-9 expression and proteolytic activity. ERK1/2 
has been linked with important targets of EWS/FLI-1 as 
IGF-1 [36] or tumor suppressor LOX [37]. Indeed, U0126 
increased sensitivity to IGF-1R antibody figitumumab 
while MEK/ERK activation via p-ERK1/2 (Thr202/
Tyr204) contributes to IGF1R-related therapies resistance 
in metastatic ES [38-39]. All these facts give evidence 
of the crucial role of MEK/ERK pathway in the pro-
metastatic effect that CAV1 exerts through MMP-9 in ES 
cells.
IQGAP1 has been described as a scaffold for MAPK 
signaling pathway [40]. Scaffold proteins coordinate many 
intracellular signaling processes assuring the correct flow 
of information inside the cell [41]. IQGAP1 behaves as a 
modulator of several cellular mechanisms as cytoskeleton 
organization or cellular adhesion, interacts with ERK2 
and MEK1/2 [19, 40] and has been associated with 
proliferation [42] and invasion [43]. First, we verified 
the expression of IQGAP1 in the ES cell lines. Stable 
silencing of IQGAP1 in A673 cells resulted in a reduction 
in p-MEK1/2 and p-ERK1/2 levels besides a marked 
decrease of MMP-9 expression, migration and invasion. 
We showed that IQGAP1 and CAV1 share localization at 
membrane protusions in ES cells. These results suggest 
that IQGAP1 could be the hub connecting CAV1 and 
MEK/ERK in ES as it has been already described in other 
neoplasias [44].
Analysis of the phosphorylation profile of 
A673 shCAV1 model revealed a reduction in RPS6 
phosphorylation as the only significant change among 
Tyr-kinase receptors. Lower p-RPS6 levels were also 
detected in TC71 shCAV1 cells. RPS6 is a cytoplasmic 
40S ribosomal protein that belongs to the S6E family 
of ribosomal proteins. RPS6 is a major substrate in the 
ribosome of protein kinases and it is involved in cell 
growth and proliferation via translation of specific mRNAs 
[23]. In six of the seven ES cell lines checked RPS6 was 
phosphorylated. In a set of ES patients we observed a 
positive correlation between high p-RPS6 levels and 
improved survival. Our observation is in agreement 
with what it has been previously described in other ES 
patients set: the association between p-mTOR protein 
overexpression and better survival [39].
RPS6 can be phosphorylated on Ser235/236 by 
RSK proteins in an ERK1/2-dependent manner [23]. 
The four RSK isoforms have been implicated in several 
neoplasias [24]. Although ES cell lines show almost the 
same level of RSK1 there are evident differences within 
them concerning the phosphorylation forms of RSK1 
and RSK2. CAV1 silencing in A673 and TC71 cells 
diminished p-RSK1 as U0126 treatment did. A673 and 
TC71 cells treatment with U0126 during 24 h caused also 
a decrease in phospho-RPS6 levels but were recovered 
24 h later. We could not detect any p-RPS6 variation in 
A673 RSK1-knockdown cells regarding controls, thus in 
ES RPS6 phosphorylation seems to be RSK1-independent. 
RSK1-knockdown did not change p-ERK1/2 levels and 
neither affected MMP-9 expression or activity. Therefore, 
RSK1 seems not to be implicated in MMP-9 regulation 
in ES. Nevertheless, RSK1 is affecting the migratory and 
invasive capacity of A673 cells. Our results agree with 
previous studies that show the crucial role of RSK1 in 
the migratory phenotype of epithelial [45] or melanoma 
cells, promoting migration through RhoA inhibition [46]. 
Conversely, in lung cancer cells RSK1 silencing increases 
cell motility [47]. So, RSK1 may have contrary effects on 
migration capacity depending on the cellular background, 
being proactive in ES cells. RSK1 inhibition did not 
affect p-ERK1/2 and p-RPS6 status and neither MMP-9 
expression nor its activity. Moreover, the experimental 
metastasis model showed no differences between RSK1 
silenced cells and controls, suggesting that RSK1 has 
no role on the ability of lung colonization of ES cells. 
However, we could verify in a new orthotopic model that 
the metastatic capacity of A673 shRSK1 cells is not only 
reduced in vitro but also in vivo. Therefore, our results 
point to RSK1 as an important pro-metastatic player in ES 
as it has been previously described in other tumors [48-
49]. We are also presenting for the first time this modified 
version of a previously described orthotopic model 
[26]. We believe that this orthotopic model recapitulates 
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more closely the metastatic steps in ES as the primary 
tumor grows in its natural environment. Resection of the 
gastrocnemius is a low-aggressive surgery that allows the 
survival of the mice with a normal mouse life for a period 
long enough for the development of distant metastases. 
Thus, this animal model may become a valuable 
experimental tool to analyze metastatic potential not only 
in ES but in other sarcomas too.
In summary, we demonstrate that CAV1 regulates 
the expression and activity of MMP-9 through the 
MEK/ERK pathway in ES being IQGAP1 the putative 
connecting node. We have also unveiled RPS6 as an 
important signaling node under CAV1 influence. Moreover 
we showed that RSK1 is a key player in ES metastasis. A 
full comprehensive understanding of ES metastatic process 
is mandatory to develop novel therapeutic strategies. 
Thus, as several clinically tested MEK/ERK inhibitors are 
available, ES patients could benefit from their application.
MATERIALS AND METHODS
Cell culture and stable transfections
A673, TC252 (gifts from Dr. Heinrich Kovar, 
Children's Cancer Research Institute, Vienna, Austria), 
RH1 (gift from Dr. Peter Houghton, Greehey Children's 
Cancer Research Institute, San Antonio, Texas, USA), 
EW7 (gift from Dr. Olivier Delattre, Institut Curie, 
Paris, France), A4573 (gift from Dr. Santiago Ramón 
y Cajal, Hospital Universitari Vall d'Hebron-Universitat 
Autònoma de Barcelona, Barcelona, Spain), TC71 and 
RD-ES (bought from Leibniz Institute DSMZ-German 
Collection of Microorganisms and Cell Cultures, 
Braunschweig, Germany) cell lines were cultured in 
RPMI 1640 (Invitrogen) supplemented with 10% heat-
inactivated fetal bovine serum (Invitrogen). All cell lines 
were incubated at 37°C in a humidified atmosphere of 
5% CO2 in air and checked regularly for mycoplasma 
infection. Exponentially growing cells within two 
sequential passages were used for all experiments. Cells 
were transfected using Lipofectamine 2000 (Invitrogen) 
following the protocols of the manufacturer. Transfected 
cells were selected with 0.4 mg/mL neomycin 
(Invitrogen) or 0.5 μg/mL puromycin (Sigma-Aldrich) 
for 14 days. CAV1 silencing was done as previously 
described [10]. pRS-shRNA anti-RSK1 was bought 
from OriGene. Antibiotic-resistant pools and individual 
clones were isolated for further analysis and maintained 
in the presence of neomycin (0.4 mg/mL) or puromycin 
(0.5 μg/mL). For MEK1/2 inhibitor treatment, A673 
and TC71 cells were seeded and after 24 h, cells were 
incubated with 20 μM U0126 (CAS number 109511-58-
2, LC Laboratories) in absence of serum for 24 and 48 h. 
Then, medium was collected for zymography and cells 
were harvested for protein or RNA extraction (described 
below).
Western blot
ES cells were lysed with radioimmunoprecipitation 
assay buffer (RIPA Buffer, Thermo Scientific) containing 
protease inhibitors (complete, Mini; Protease Inhibitor 
Cocktail Tablets, Roche) and phosphatase inhibitors 
(PhosStop, Phosphatase Inhibitor Cocktail Tablets, Roche) 
and centrifuged at 13,000 g, at 4 ºC, for 30 minutes. The 
protein content of the supernatants was determined with 
the BCA assay system (Pierce). Lysate aliquots (50 μg) 
were resolved by 8, 10 or 12% SDS-PAGE (depending on 
the size of the protein that was analyzed) and transferred 
onto nitrocellulose membranes (0.2 mm, Bio-Rad). After 
blocking with 5% skimmed milk in Dulbecco’s PBS 
(DPBS) containing 0.1% Tween20 at room temperature 
for 1 h, membranes were incubated overnight at 4 ºC with 
the appropriate primary antibody (CAV1 #610059 from 
BD Transduction Lab; ERK1/2 #4695, Phospho-ERK1/2 
Thr202/Tyr204 #4376, MEK1/2 #4694, Phospho-MEK1/2 
Ser217/221 #9154, RPS6 #2217, Phospho-RPS6 Ser235/236 
#4858, RSK1 #9333, Phospho-RSK1 Thr359/Ser363 #9344, 
RSK2 #9340, Phospho-RSK2 Ser227 #3556 from Cell 
Signaling Technology, IQGAP1 #05-504 from Millipore). 
Blots were then incubated at room temperature for 1 h with 
a horseradish peroxidase-conjugated secondary antibody 
(goat anti-rabbit and goat anti-mouse) and the peroxidase 
activity was detected by enhanced chemiluminescence 
(Pierce) following the instructions of the manufacturer. 
Immunodetection of α-tubulin (#ab28439 from Abcam) was 
used as a loading reference. Measure of the intensity of the 
bands was done with Image J software (NIH).
Gelatin zymography
Metalloproteinase activity was analyzed by gelatin 
zymography. In brief, cells were cultivated in serum-free 
medium for 48 h. Conditioned medium was then collected 
and concentrated to one-tenth of its original volume and 
electrophoresed on SDS polyacrylamide gels (10%) 
containing 120 μg/mL of gelatin. After electrophoresis, the 
gel was incubated for 60 minutes in 2.5% Triton X-100 
and left overnight at 37°C in 50 mmol/L of Tris (pH 
8.0)/5 mmol/L CaCl2. Then, the gels were stained with 
0.1% Coomassie brilliant blue and destained with 10% 
isopropanol in 10% acetic acid, and the gelatinolytic activity 
was identified as transparent bands in the Coomassie brilliant 
blue–stained background. Measure of the intensity of the 
bands was done with Image J software (NIH).
Transwell migration assay
1.5×105 cells in 150 μL free-serum media were 
added to the top chamber of 8 μm Costar polycarbonate 
transwells (Transwell Permeable Supports-Corning), while 
in the bottom chamber 500 μL of complete media were 
added. After 24 h for A673 and 36 h for TC71, cells on the 
upper membrane surface were removed and migratory cells 
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on the membrane underside were fixed using 70% ethanol 
and stained using 0.1% crystal violet solution (Invitrogen). 
The number of migrated cells (crystal violet stained ones) 
on the underside membrane was determined counting by 
optical microscopy. Data were presented as the average 
number of migratory cells in 5 high-power fields (100X). 
Each experiment was performed in triplicate, and then the 
data were averaged for statistical analysis.
Matrigel invasion assay
8 μm Costar polycarbonate transwells (Transwell 
Permeable Supports-Corning) were coated with 50 μl cold 
Matrigel (BD Biosciences) diluted 1:20 in RMPI 1640 and 
placed in a 37°C incubator for 6 h. Cells were seeded, 
stained and counted as in the migration assay, but stopping 
the reaction after 60 h.
Reverse transcription-PCR
Total RNA (2 μg), extracted using the RNeasy 
Mini Kit (Qiagen), was used for cDNA synthesis with 
SuperScript II Reverse Transcriptase (Invitrogen). 
Amplifications of MMP-9 and β-actin were 
carried out using specific primers (forward primer 
GAGGAATACCTGTACCGCTATG, reverse primer 
CAAACCGAGTTGGAACCAC for MMP-9; forward 
primer CGGGACCTGACTGACTACCTC, reverse primer 
CTTCATTGTGCTGGGTGC for β-actin) designed using 
the Oligo 6.0 software (National Bioscience). For each set 
of primers, the number of cycles was adjusted so that the 
reaction end points fell within the exponential phase of 
product amplification, thus providing a semi-quantitative 
estimation of relative mRNA abundance. Experiments 
were carried out at least twice.
Quantitative real time PCR
Quantitative reverse transcription-PCR (qRT-PCR) 
was performed under universal cycling conditions on 
an ABI 7300HT instrument (Applied Biosystems) using 
commercially available MMP-9 probe (Hs00234579_
m1) and mastermix (all from Life Technologies). Cycle 
threshold (CT) values were normalized to β-actin (ACTB). 
Experiments were performed at least three times and in 
triplicates. Relative expression level of the target gene 
among the different samples was calculated using the 
ΔΔCT method [50]. Mean values and standard deviations 
were calculated based on the results of three biological 
replicates at least.
Receptor tyrosine kinase (RTK) phosphorylation 
array
Total protein extracts from A673 CAV1 knockdown 
cells were analyzed with PathScan® RTK Signaling 
Antibody Array Kit (Chemiluminescent Readout) 
(Cell Signaling Technology #7982), that allows for the 
simultaneous detection of 28 receptor tyrosine kinases 
and 11 important signaling nodes, when phosphorylated at 
tyrosine or other residues. Manufacturer instructions were 
followed. Measure of the intensity of the bands was done 
with Image J software (NIH).
Sucrose gradient
Sucrose gradient was performed as described 
elsewhere [51]. Briefly, two 10 cm dishes of A673 and 
TC71 cells were washed twice with cold PBS and 
resuspended in 500 μl of homogenization buffer (50 
mmol/L Tris-HCl, pH 7.5, 150 mmol/L sodium chloride, 
and 5 mmol/L EDTA), supplemented with 10 μg/mL 
leupeptin and 10 μg/ml aprotinin. Cells were disrupted 
at 4°C by nitrogen cavitation in a cell disruption bomb 
(Parr Instrument Company) at 800 psi for 15 minutes and 
collected dropwise. Afterward, cells were passed back and 
forth through a 22-gauge needle 25 times at 4°C. Nuclei 
and unbroken cells were removed by centrifugation at 
1,600 g in a MLA-130 rotor (Beckman Coulter) for 5 
minutes at 4°C. The resulting supernatant (500 μL) was 
mixed with an equal volume of 2.5 M sucrose and loaded 
at the bottom of a discontinuous sucrose gradient formed 
by layers of 200 μL of 30, 25, 20, 15, 10, and 5% sucrose 
(wt/vol) freshly prepared in homogenization buffer. 
Gradients were centrifuged in a TLS-55 swinging-rotor 
(Beckman Coulter) without brake at 166,000 g for 3 h at 
4°C. Five fractions of 280 μl were collected from the top 
in addition to a final lower fraction of 700 μL by using 
a CentriTube Slicer (Beckman Coulter). The gradients 
shown in the figures are representative of at least two 
independent experiments.
Immunofluorescence
For immunofluorescence, ES cells were cultured in 
sterile slides (Millicell EZ slide from Millipore) for 24 h 
until 60-70% confluence. Expression of CAV1 in ES was 
analyzed using a rabbit polyclonal antibody with a 1:1000 
dilution (CAV1 #610059, BD). IQGAP1 expression 
was analyzed using an antibody at a 1:100 dilution 
(IQGAP1 #05-504, Millipore). Cells were fixed with 4% 
formaldehyde, washed thrice in Dulbecco's PBS (DPBS), 
permeabilized in 0.1% Triton for 2 minutes, blocked for 
1 h in blocking buffer (10% fetal bovine serum in DPBS) 
and incubated with primary antibodies overnight. Cells 
were then washed thrice in DPBS for 5 minutes each 
followed by a 1 h incubation with secondary antibodies 
(Alexa Fluor 488 goat anti-mouse and Alexa Fluor 594 
goat anti-rabbit; Invitrogen). Nuclei were counterstained 
with 4ʹ,6ʹ-diamidino-2-phenylindole (DAPI, Invitrogen) 
for 5 minutes. Then, cells were washed twice in DPBS for 
10 minutes and twice in distilled water for 10 minutes, and 
mounted in ProLong Gold antifade reagent (Invitrogen). 
Photographs were taken with a Leica TCS SP5 spectral 
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confocal microscope (argon, 405 diode and DPSS561 
lasers) using a lambda blue 63×1.35 numerical aperture 
oil objective. Images were analyzed with the Image J 
software (NIH).
Tissue samples and immunohistochemistry
Tumor samples were processed and p-RPS6 
expression analyzed as described elsewhere [10]. p-RPS6 
was detected with a 1:400 dilution of a phospho-RPS6 
Ser235/236 antibody (#4858, Cell Signaling Technology).
Experimental metastasis assay
The in vivo experimental metastasis model was 
performed as described previously [10]. Briefly, 2×106 
cells resuspended in 100 μL of saline solution were injected 
intravenously (i.v.) in the tail of athymic nude mice 
(BALB/cnu/nu) purchased from Harlan. After 45 days 
mice were euthanized and lungs were excised for further 
analysis. Tumors were fixed in 4% paraformaldehyde and 
embedded in paraffin. Metastases were counted under an 
optical microscope. Data are given as mean ±SD.
In vivo orthotopic xenograft model
2×106 cells resuspended in 0.1 mL of PBS were 
injected using a 25 gauge needle into the gastrocnemius 
muscles of 6 weeks old female athymic nude mice 
(BALB/cnu/nu) from Harlan (n=7 for each clon). The 
growth of primary tumors was monitored by periodical 
measurements of the limb using a caliper. Tumor volume 
was calculated according to the formula (L×l2/2), where 
L is the longer diameter and l the shorter diameter. 
Once primary tumor-bearing limbs reached a volume of 
800 mm3 (18-20 days after inoculation), gastrocnemius 
muscles were surgically resected to reduce morbidity 
associated with excessive tumor growth and to allow 
metastases to form. Mice were maintained anesthetized 
in a 3% isofluorane chamber during all the surgical 
procedure. Tumor-bearing gastrocnemius were identified 
by Achilles tendon and completely resected till the knee. 
Afterwards, the injury was sealed using a TB10 silk suture. 
Mice received an i.p. injection of meloxicam (1 mg/kg) as 
analgesia after surgery and kept under a warm lamp until 
recovery that was almost complete after 15 minutes. At day 
60 after inoculation mice were euthanized and lungs were 
harvested and fixed in 10% buffered paraformaldehyde 
for histopathological analysis. However, 20% of mice 
developed local relapses in areas adjacent to the surgery 
site so they were euthanized before the experiment 
end-point but also included in the experiment. In both 
metastasis models animal care procedures were followed 
according to the institutional guidelines for the care and 
use of laboratory animals. Ethics approval was provided 
by the locally appointed ethics committee from IDIBELL, 
Barcelona, Spain.
Statistical analysis
Two-tailed Student's t-test was used to determine 
statistical significance. Unless otherwise stated, 
experiments were performed thrice; p ≤ 0.05 was 
regarded as significant. The analysis was done using 
either Microsoft Excel or GraphPad Prism software.
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